What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Gene
Brent L. Wood spends much of his time researching Immunology, Internal medicine, Oncology, Cancer research and Transplantation.
His research investigates the connection between Immunology and topics such as Haematopoiesis that intersect with problems in CD34 and EP300.
His Internal medicine study frequently links to other fields, such as Gastroenterology.
His Oncology research incorporates elements of University hospital, EuroFlow, Bioinformatics, Consensus conference and Cell lineage.
His research integrates issues of Janus kinase 2, Janus kinase, Mutation, STAT5 and Philadelphia chromosome in his study of Cancer research.
Brent L. Wood interconnects Chemotherapy and Cancer biomarkers in the investigation of issues within Transplantation.
His most cited work include:
- The genetic basis of early T-cell precursor acute lymphoblastic leukaemia (1109 citations)
- CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients (939 citations)
- Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia (694 citations)
What are the main themes of his work throughout his whole career to date?
His scientific interests lie mostly in Internal medicine, Oncology, Minimal residual disease, Immunology and Leukemia.
His work deals with themes such as Gastroenterology and Surgery, which intersect with Internal medicine.
His study in Oncology is interdisciplinary in nature, drawing from both Hazard ratio, Methotrexate and Acute lymphocytic leukemia, Lymphoblastic Leukemia.
As part of the same scientific family, Brent L. Wood usually focuses on Minimal residual disease, concentrating on Flow cytometry and intersecting with Antibody and Antigen.
The concepts of his Immunology study are interwoven with issues in CD34, Haematopoiesis and Cancer research.
The study incorporates disciplines such as Progenitor cell and Cord blood in addition to Haematopoiesis.
He most often published in these fields:
- Internal medicine (55.29%)
- Oncology (36.00%)
- Minimal residual disease (29.41%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (55.29%)
- Oncology (36.00%)
- Myeloid leukemia (18.35%)
In recent papers he was focusing on the following fields of study:
Brent L. Wood mainly focuses on Internal medicine, Oncology, Myeloid leukemia, Minimal residual disease and Leukemia.
Brent L. Wood applies his multidisciplinary studies on Internal medicine and Cog in his research.
His research in Oncology intersects with topics in Clinical trial, Chemotherapy, Young adult, Randomized controlled trial and Transplantation.
His biological study spans a wide range of topics, including Hematopoietic stem cell transplantation, Disease, Myeloid, NPM1 and Flow cytometry.
The various areas that Brent L. Wood examines in his Minimal residual disease study include Childhood Acute Lymphoblastic Leukemia, Acute leukemia, Surrogate endpoint and Confidence interval.
His Leukemia research includes elements of Neoadjuvant therapy, Cancer research, Haematopoiesis and Burkitt's lymphoma.
Between 2017 and 2021, his most popular works were:
- Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. (388 citations)
- PAX5 -driven subtypes of B-progenitor acute lymphoblastic leukemia (105 citations)
- The genetic basis and cell of origin of mixed phenotype acute leukaemia (86 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
Internal medicine, Oncology, Cancer research, T cell and Minimal residual disease are his primary areas of study.
He has researched Oncology in several fields, including Chemotherapy, Young adult, Randomized controlled trial, Leukemia and Transplantation.
His Leukemia study frequently draws connections to other fields, such as Haematopoiesis.
The Haematopoiesis study which covers Hematopoietic stem cell transplantation that intersects with Retrospective cohort study.
His studies deal with areas such as Chemotherapy regimen, Phenotype, Receptor, Chimeric antigen receptor and Multiple myeloma as well as Cancer research.
His Minimal residual disease study combines topics in areas such as Disease, Hematopathology, MEDLINE and Intensive care medicine.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
